Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 33.3%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%

Idraparinux vs usual care

Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis

Idraparinux showed no clear difference in recurrent venous thromboembolism compared with standard therapy (low certainty).

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 0.98 [0.64, 1.48]
1 study · 2904 participants
Low

Low molecular weight heparin and idraparinux vs usual care

Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis

It is very uncertain whether low molecular weight heparin and idraparinux changes recurrent venous thromboembolism compared with standard therapy (very low certainty).

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 1.51 [0.26, 8.9]
1 study · 263 participants
Very low

Idrabiotaparinux vs idraparinux

Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis

Idrabiotaparinux showed no clear difference in recurrent venous thromboembolism compared with idraparinux (low certainty).

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 0.72 [0.31, 1.69]
1 study · 757 participants
Low